If you liked this article you might like

Surveying the NASH Drug Landscape
Sarepta Pops on Bullish Sentiment Around Duchenne Therapy, PDL Up on Merck Deal: Biotech Movers
Takeaways and Observations; The Good, the Bad and the Ugly: Doug Kass' Views
Jim Cramer -- Eli Lilly Is the New 'Darling' of Big Pharma